Heron Therapeutics is trading at $0.36, down 5.41% in pre-market, with no clear company-specific catalyst identified.
- The company’s official news page lists its Q2 results on August 10, not October 8.
- Its next earnings date is listed as November 10. The provided market context is mixed to lower, but does not confirm the cause of the decline.
- Available information does not establish why shares are lower.